Join
Live feed
·
PRReleasevia Quantisnow
Syndax Pharmaceuticals Inc. logo

Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
SNDX· Syndax Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SNDX (Syndax Pharmaceuticals Inc.) and more on Quantisnow.